Outsourcing Clinical Research

What will happen to the world of outsourcing?

The Pharma world space of 3 major global players has united to form the world's FIRST cancer group to focus towards the emerging markets of Asia to target Stomach and Lung cancer. The news release has got flashed at 6-7 major web sites. An individual news clip was flashed by Elli Lilly in the late evening hours yesterday as well which spoke of its initiatives to start the research work form Singapore. There were mentions of mainly the people from Elli Lilly in Singapore and China in the News release.

The world of the Pharmaceutical Industry has changed. The drug majors are uniting themselves with the changing times, have decided to "mutually share" database s for cancer drug development and move in unison towards the emerging markets.

If this is so, then what should be the subsequent strategic initiatives at the CRO's (the outsourcing providers) in the emerging markets?

Should the CRO's "act" in a similar manner as the Pharma companies or prepare to understand the market on their own with individual capabilities?

This is question which can be answered only when the outsourcing market takes a DECISIVE turn in a direction which today many forecasting experts are trying to understand.

This blog is co-posted with the Veeda Clinical Research Blog